The fibrinogen-to-albumin ratio (FAR), integrating both pro-inflammatory (fibrinogen) and anti-inflammatory (albumin) pathways, has emerged as a novel inflammatory biomarker demonstrating strong associations with adverse cardiovascular outcomes in CAD populations [11, 12]. The gene discussed is ALB; the disease is coronary artery disorder.